Burns – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Burns – Pipeline Review, H2 2017’, provides an overview of the Burns pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Burns

The report reviews pipeline therapeutics for Burns by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Burns therapeutics and enlists all their major and minor projects

The report assesses Burns therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Burns

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Burns

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AlgiPharma AS

Alliance Pharma Plc

Amarantus Bioscience Holdings Inc

American Gene Technologies International Inc

Anterogen Co Ltd

CytoTools AG

Destiny Pharma Ltd

Lakewood-Amedex Inc

Madam Therapeutics BV

MediWound Ltd

Phagelux Inc

Phosphagenics Ltd

Se-cure Pharmaceuticals Ltd

Stratatech Corp

USV Pvt Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Burns - Overview 6

Burns - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Burns - Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Burns - Companies Involved in Therapeutics Development 23

AlgiPharma AS 23

Alliance Pharma Plc 23

Amarantus Bioscience Holdings Inc 24

American Gene Technologies International Inc 24

Anterogen Co Ltd 25

CytoTools AG 25

Destiny Pharma Ltd 26

Lakewood-Amedex Inc 26

Madam Therapeutics BV 27

MediWound Ltd 27

Phagelux Inc 28

Phosphagenics Ltd 28

Se-cure Pharmaceuticals Ltd 29

Stratatech Corp 29

USV Pvt Ltd 30

Burns - Drug Profiles 31

(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 31

A-3APO - Drug Profile 32

AG-110 - Drug Profile 34

albumin (recombinant) - Drug Profile 35

AyuV-25 - Drug Profile 36

Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile 37

bromelains - Drug Profile 38

Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile 42

Cell Therapy for Dermatology and Immunology - Drug Profile 44

ENERGIF-711 - Drug Profile 46

epidermal growth factor biosimilar - Drug Profile 47

Gene Therapy for Burns - Drug Profile 48

IMSP-001 - Drug Profile 49

ISN-001 - Drug Profile 50

lidocaine hydrochloride - Drug Profile 52

Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 53

Neu-2000 - Drug Profile 54

NJ-01SS - Drug Profile 56

Nu-2 - Drug Profile 57

Oligomer G for Burn Wounds - Drug Profile 58

P-12 - Drug Profile 59

P-148 - Drug Profile 60

PEP-04 - Drug Profile 61

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 62

Recombinant Protein to Agonize EPCR for Wounds and Burns - Drug Profile 63

SC-106 - Drug Profile 64

SFR-9X0125 - Drug Profile 65

silver sulfadiazine - Drug Profile 66

Small Molecules for Burns - Drug Profile 67

sodium hypochlorite - Drug Profile 68

SST-024 - Drug Profile 69

Vanadis-02 - Drug Profile 70

XF-70 - Drug Profile 71

Burns - Dormant Projects 72

Burns - Discontinued Products 74

Burns - Product Development Milestones 75

Featured News & Press Releases 75

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

List of Tables

Number of Products under Development for Burns, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Burns – Pipeline by AlgiPharma AS, H2 2017

Burns – Pipeline by Alliance Pharma Plc, H2 2017

Burns – Pipeline by Amarantus Bioscience Holdings Inc, H2 2017

Burns – Pipeline by American Gene Technologies International Inc, H2 2017

Burns – Pipeline by Anterogen Co Ltd, H2 2017

Burns – Pipeline by CytoTools AG, H2 2017

Burns – Pipeline by Destiny Pharma Ltd, H2 2017

Burns – Pipeline by Lakewood-Amedex Inc, H2 2017

Burns – Pipeline by Madam Therapeutics BV, H2 2017

Burns – Pipeline by MediWound Ltd, H2 2017

Burns – Pipeline by Phagelux Inc, H2 2017

Burns – Pipeline by Phosphagenics Ltd, H2 2017

Burns – Pipeline by Se-cure Pharmaceuticals Ltd, H2 2017

Burns – Pipeline by Stratatech Corp, H2 2017

Burns – Pipeline by USV Pvt Ltd, H2 2017

Burns – Dormant Projects, H2 2017

Burns – Dormant Projects, H2 2017 (Contd..1), H2 2017

Burns – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Burns, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports